The expression levels of GAS5 were found to be increased in almost all the cancer cells treated with sorafenib compared to cells exposed to DMSO (except SKHep1C3) proving that sorafenib may up-regulate GAS5 not only in different HCC cell lines but also in renal and breast cancer cells. This evidence concerns the gene GAS5 and cancer.